Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BioNTech SE's shares outstanding for the quarter that ended in Mar. 2026 was 253 Mil.
BioNTech SE's quarterly shares outstanding
increased
from Dec. 2025 (251 Mil) to Mar. 2026 (253 Mil).
It means BioNTech SEissued new shares from Dec. 2025 to Mar. 2026 .
BioNTech SE's annual shares outstanding
increased
from Dec. 2024 (240 Mil) to Dec. 2025 (251 Mil).
It means BioNTech SEissued new shares from Dec. 2024 to Dec. 2025 .
BioNTech SE (NAS:BNTX) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
BioNTech SE Shares Outstanding (EOP) Related Terms
BioNTech SE Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNTX vs INCY, INSM, ROIV: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, BioNTech SE's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where BioNTech SE's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 253 Mil mean?
BioNTech SE (BNTX) has a Shares Outstanding (EOP) of 253 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on BioNTech SE and its competitors.
Is BioNTech SE's Shares Outstanding (EOP) too high?
BioNTech SE's current Shares Outstanding (EOP) is 253 Mil. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Shares Outstanding (EOP) compare to INCY and INSM?
BioNTech SE's Shares Outstanding (EOP) of 253 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on BioNTech SE and its competitors. BioNTech SE's current Shares Outstanding (EOP) is 253 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $88.28, compared to a current price of $93.05 — trading 5.4% above its estimated fair value. The current Shares Outstanding (EOP) is 253 Mil. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Shares Outstanding (EOP) is 253 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $93.05 is trading 5.4% above its estimated GF Value™ of $88.28.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
Shares Outstanding (EOP): 253 Mil
GF Value™: $88.28 vs. price of $93.05 (5.4% above fair value)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
